Tuesday , August 16 2022

The new treatment helps to counteract dangerous hazardous allergies


If approved, new treatments for peanut allergy will allow children to eat peanuts without significant allergic reactions.

Share on Pinterest
Some peanuts may even be dangerous for some children. Getty Images

For children with peanut allergies, every corner of the outside world is alarming.

The effect of the amount of peanuts after crispy cake, cakes or other dishes expires with severe allergic reaction and even hospitalization.

The results of the new study can help not only children, but also their parents, to reinforce new treatments that reduce the risk of possible deaths.

Treatment is an antidote to peanut allergy. It also does not allow children to eat whole peanut butter and jelly sandwiches. Instead, the goal is to feed the little peanuts.

"One or two nut's safe drinking is a great improvement in children's quality of life – for example, when they go to your friend's home during the night or roast, they can avoid peanuts, but they can still drink in a small quantity," says Dr. Stefan Tilles, one of the authors of the study and former president of the American College of Allergy, Astma and Immunology.

For many children with allergies, this is a good protection.

"Some kids do not have to eat with peanut butter. They are the Master of Smoking and Strain Research at Stanford University, Shon N. Parker's clinical doctor, Dr. Tina Syncher, protects her from being involved in the study.

The results of the study were conducted on Sunday in the Seattle College of Allergy, Astma and Immunology in the United States and published in The New England Journal of Medicine on Monday.

During the study, 372 children with known allergy to peanut additives increase the daily peanut protein every six months, starting in minutes. The next six months are a "dose saving", that is, a peanut equalizer.

This type of treatment is called oral immunotherapy and is designed to enhance the immune system's resistance to allergens.

One year later, two thirds of people between the ages of 4 and 17 can use a peanut protein of 600 mg worth of "no mild symptoms" – two peanut butter.

On the contrary, in the placebo group, 4 percent of 124 children who received powdered powder could not tolerate the same amount of peanut protein.

Half of the children in the treatment group can use more than 1,000 milligrams of peanut protein during the meal.

However, this treatment may not work for all people.

During the study, almost all children had negative reactions. The most common cause of children receiving peppermint was gastroenteric disorders, vomiting, nausea, skin ache, coughing and irritation.

About a third of children in the treatment group have easy signs compared to 50 percent in the placebo group.

Cancer was 4.3 per cent in the treatment group and less than 1 per cent of children in the placebo group.

Also, in the study, 14 percent of the treatment group received epinephrine injection for severe allergic reactions compared with 6.5 percent of children in the placebo group.

Some side effects were insufficient, and some children did not go until the end of the study – 12 percent of the treatment group. The syndrome surprises by this high level.

"We always see it in the clinic," he said. "Some children do not allow immunotherapy in mouth. For example, some of them have anaphylactic reactions in the dose they take for two to three weeks. In the real world there are many variables. "

Unfortunately, it is impossible to predict which children have a bad reaction.

"It's hard to know who will be cured in 1 or 2 years," Tils said. "But a year after that investigation, at least, most of the patients say they are still working well."

While the subject of the study was allergic community, there were several warnings. The protein used in the study was developed by the Aimmune Therapeutics, which is known as the AR101, which has developed and sponsored clinical trials. Five of 13 main authors are Aimmune Therapeutics, the New York Times reported. Others are paid for service at the Scientific Advisory Board of the Company.

Treatment should be obtained from the US Department of Food and Drug Administration. But it can be a big demand.

According to the Research & Education website for food allergy, between 1997 and 2008, peanut or peanut allergy to American children increased 3 times.

Approximately 40% of children with food allergies experience severe allergic reactions such as anaphylaxis.

This is not the only possible treatment for the hazard and death of food allergy.

At present, several treatments for peanut and other nutritional allergies are underway. According to Synch, many of them are designed to help children with oral immunotherapy.

DBV Technologies filed an application to the FDA for a patch of immunotherapy, which provides a milligram of microbes rather than a minimal amount of peanut butter.

Sanofi works in the form of immunotherapy. In addition to peanut protein, this includes a compound that boosts the immune system's resistance to allergy to peanuts.

Along with other tested immunotherapy, omalizumab – Xolair applies allergy medicine. This drug blocks the antibody that participates in the poisonous allergic reaction.

Stanford researchers are testing the DNA vaccine, which reduces inflammatory response to nuts. The vaccine also does not contain specific peanut proteins, so the risk of anaphylactic reaction during treatment is low.

Not even the syndrome.

"If anything, we will see a growing peanut allergy every year," he said. "But we go for a lot of treatments. We also try to learn more about food allergy to help preventive strategies. "

In one study in 2015, some adolescents from early on to peanuts have shown that they can reduce the risk of developing peanut allergy.

This treatment can offer children more than just "avoiding, preventing, preventing" and offering more options than the "EpiPens".

"If the treatment works, then it will be protected when there is a child's equivalent," said Singer. "We call no" no dog "if the child suddenly tastes cookie, they will not be taken to hospital."

However, there is one type of research, but it can significantly reduce the need for this type of treatment – hypoallergenic peanutrition genetic engineering, researchers are now working.

Source link